- Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxinTim Eisen
Cambridge University Health Partners, Addenbrooke s Hospital, Cambridge, UK
Curr Oncol Rep 16:370. 2014..Naptumomab estafenatox has been clinically tested in a range of solid tumors with focus on renal cell carcinoma. This review looks at the clinical experience with the new immunotoxin and its potential...
- Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen
Cambridge University Health Partners, Cambridge, UK
Lancet Oncol 13:1055-62. 2012..This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell carcinoma...
- Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinomaB P Fairfax
Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LJ, UK
BMC Cancer 12:590. 2012..The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort...
- Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen
Department of Oncology R4, Cambridge Biomedical Research Centre, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, UK
Br J Cancer 105:353-9. 2011....